SequelSEC

Eloxx Pharmaceuticals, Inc. ELOX

Biological Products, (No Diagnostic Substances) · CIK 0001035354 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
Unavailable
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Eloxx Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Eloxx Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312014-06-30
RevenueUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating incomeUnavailableUnavailableUnavailableUnavailable
Net incomeUnavailableUnavailableUnavailableUnavailable
Research & developmentUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Eloxx Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312014-06-30
Cash & equivalents$4.78M$111.00K$1.13M$6.11M
Total assets$5.27M$2.98M$1.71M$33.33M
Current assets$5.27M$2.98M$1.55M$7.22M
Total liabilities$17.18M$27.31M$24.31M$5.84M
Current liabilities$17.18M$27.31M$22.70M$1.83M
Total equity incl. NCI-$11.91M-$24.34M-$22.60M$27.49M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable$43.13K
GoodwillUnavailableUnavailableUnavailable$13.90M
Long-term debt$0$0$1.61MUnavailable
Accounts payable$2.71M$5.35M$5.70M$901.18K

Cash flow

Eloxx Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312014-06-30
Operating cash flowUnavailableUnavailableUnavailableUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailable
Financing cash flowUnavailableUnavailableUnavailableUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailable

Derived

Eloxx Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312014-06-30
Free cash flowUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable
Current ratio0.31x0.11x0.07x3.96x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ELOX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-17View SEC filing
10-Q · Filed 2023-11-13View SEC filing
10-Q · Filed 2023-08-11View SEC filing
10-Q · Filed 2023-05-12View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.